Latest research on 5-FU

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]

Latest findings

In our institution, localized concurrent chemoradiotherapy (CCRT) for HCC consisted of local RT and hepatic arterial infusion chemotherapy (HAIC) of 5-Fluorouracil (5-FU); CCRT was performed to enhance the effect of local RT and to reduce the risk of intrahepatic metastasis. [source, 2016]
Patients with advanced pathological stages were further treated with chemotherapy (Cisplatin and Fluorouracil for four to six cycles; n=24) or chemoradiation (55–65 Gy during 6–7 weeks for radiation; n=49). [source, 2016]
A combination of 5-Fluorouracil (5-FU) and Leucovorin (LV) was the standard regimen for advanced colorectal cancer during the 1980s and 1990s. [source, 2016]
After the year 2000, FOLFOX (Oxaliplatin plus 5-FU and LV) and FOLFIRI (Irinotecan plus 5-FU and LV) were developed and modified over the course of several years. [source, 2016]
Meanwhile, regimens including easy-to-administer oral agents were demanded, because both FOLFOX and FOLFIRI require continuous infusion of 5-FU for 2 days, which was not convenient in practice. [source, 2016]
The costs associated with drug administration were higher for oxaliplatin-based regimens (FOLFOX, etc.) than for irinotecan-based regimens (IRIS, etc.) because IRIS regimens did not require continuous infusion of 5-FU. [source, 2016]
Operation fees for placement of a central venous access port for continuous infusion of 5-FU were high for oxaliplatin-based regimens, because most FOLFOX regimens were used before FOLFIRI in this study. [source, 2016]
In patients with colorectal cancer in the FAS and PAS (n=153 and n=71, respectively), 5-Fluorouracil (5-FU) plus Oxaliplatin (14% in both populations), 5-FU plus Irinotecan (13% and 20%), Capecitabine plus Oxaliplatin (12% and 10%), and 5-FU plus Irinotecan plus bevacizumab (9% and 11%) were the most common “standard” regimens. [source, 2016]
Of the “non-standard” regimens used, 5-FU (18% in both populations), Irinotecan (12% and 13%), and Oxaliplatin (11% and 10%) were the most commonly used agents (for FAS and PAS, respectively). [source, 2016]
Subsequently, positive effects were obtained in the study that combined continuous low dose rate irradiation and concurrent infusion of Bleomycin, Cyclophosphamide, cis-platinum, 5-Fluorouracil, Actinomycin D, and Mitomycin C, which is chemoradiotherapy. [source, 2016]